FARYDAK

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, UK.

Active ingredients

The drug FARYDAK contains one active pharmaceutical ingredient (API):

1	Panobinostat UNII HN0T99OO4V - PANOBINOSTAT LACTATE
	Panobinostat is a histone deacetylase (HDAC) inhibitor that inhibits the enzymatic activity of HDACs at nanomolar concentrations. HDACs catalyse the removal of acetyl groups from the lysine residues of histones and some non-histone proteins. Inhibition of HDAC activity results in increased acetylation of histone proteins, an epigenetic alteration that results in a relaxing of chromatin, leading to transcriptional activation.
	Read more about Panobinostat

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
FARYDAK Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XH03	Panobinostat	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XH Histone deacetylase (HDAC) inhibitors
Discover more medicines within L01XH03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1696068, 1696079, 1696080, 1696091, 1696103, 1696114, 1696125, 1696136, 1696147
FR	Base de données publique des médicaments	60937038, 62990388, 65638805
GB	Medicines & Healthcare Products Regulatory Agency	324036, 324044, 324047
JP	医薬品医療機器総合機構	4291040M1023, 4291040M2020
LT	Valstybinė vaistų kontrolės tarnyba	1077849, 1077850, 1077851, 1077852, 1077853, 1077854, 1077855, 1077856, 1077857
NL	Z-Index G-Standaard, PRK	128708, 128716, 128724
PL	Rejestru Produktów Leczniczych	100350004, 100350091, 100350100
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66904001, W66904002, W66904003, W66905001, W66905002, W66905003, W66906001, W66906002, W66906003
SG	Health Sciences Authority	15071P, 15072P, 15073P
US	FDA, National Drug Code	0078-0650, 0078-0651, 0078-0652, 73116-100, 73116-101, 73116-102